DAY101-EAP, Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma
What is the goal of the study?
To learn more about this study, please email the study team member listed below.
Who can participate in the study?
Please contact the study team listed below to learn more.